Wearable activity tracking devices for patients with Multiple sclerosis (MS) can be used to collect and share their mobility data to their clinicians.
Dr.Richard Rudick, Vice president, Value Based Medicine, Biogen said, "MS impairs the ability to walk for many people with MS, yet we only assess walking ability in the limited time a patient is in the doctor's office. Consumer devices can measure number of steps, distance walked, and sleep quality on a continuous basis in a person's home environment. These data could provide potentially important information to supplement office visit exams."
Multiple Sclerosis
Multiple sclerosis can be a severely disabling autoimmune disease that affects the myelin or insulating layer of the nerve fibers and typically has remissions and relapses
Advertisement
The study was conducted to assess the feasibility of using a consumer wearable device to monitor activity among people with MS in a real-world setting. Fitbit One™ activity trackers were provided to 248 subjects. The three-week study showed that participants took a total of 15 million steps and walked 6,820 miles, the distance from Boston to Beijing.
"I got positive reinforcement to do more each day, and that really encouraged me. The Fitbit also allowed me to track what I was eating and how I was sleeping. I made more positive choices as a result," said Annette Smiling, a study participant who had never used a wearable activity tracker before.
Source: Medindia
Source: Medindia
Chronic Cerebrospinal Venous Insufficiency (CCSVI) is Not Associated With Multiple Sclerosis
The medical fraternity is divided over the theory whether chronic cerebrospinal venous insufficiency is linked with multiple sclerosis. Here's what the latest research says.
Advertisement
 Experimental Drug Repairs Nerve Damage Caused by Multiple Sclerosis in TrialImproved antibody anti-LINGO-1 was given to people suffering from acute optic neuritis. About half of those people with optic neuritis could develop MS. | Advertisement
|
Results of Multiple Sclerosis Drug Trail to be Presented at Neurology Annual Meeting
The trail investigates the efficacy and safety of MD1003 drug in the treatment of primary and secondary progressive Multiple Sclerosis.
Advertisement
Recommended Reading
Latest Research News
New study findings delineate how aging affects the immune response following Spinal cord injury (SCI) and highlight the participation of the spinal cord meninges in repair.
A recent clinical trial suggests that the first medication therapy to reduce the progression of nearsightedness in children could be on the way.
Autoimmune disorders were found to be linked to Sjogren's, systemic lupus erythematosus, and systemic sclerosis.
Successful brain pacemaker implantation has helped a 51year old Parkinson's disease patient to revitalize her quality of life.
Recent recommendations on lifestyle behaviors to prevent progression of rheumatic and musculoskeletal diseases revealed.